Skoči na glavni sadržaj

Pregledni rad

https://doi.org/10.5599/admet.5.3.442

The function and regulation of PD-L1 in immunotherapy

Libin Guo ; Faculty of Health Sciences, University of Macau, Macau SAR
Yao Lin ; College of Life Sciences, Fujian Normal University, Fuzhou, Fujian Province, China
Hang Fai Kwok ; Faculty of Health Sciences, University of Macau, Macau SAR


Puni tekst: engleski pdf 725 Kb

str. 159-172

preuzimanja: 1.538

citiraj


Sažetak

PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors. PD-L1 can regulate tumor microenvironment or tumor related immune response through suppressing T cell or NK cell mediated immune response. PD-L1 expression is regulated by various cytokines, such as LPS, GM-CSF, IL-4, TGF-β, TNF-α. PD-1 and PD-L1 are the members of B7 and CD28 superfamily, respectively. The B7/CD28 interaction plays a central role in immune tolerance. PD-L1 can bind to PD-1, which leads to the suppression of lymphocyte activation and apoptosis of lymphocytes. Anti-PD-L1 therapy is one of the immunotherapies to treat cancer (especially solid tumor). PD-L1 expression may be associated with efficacy of anti PD-1/PD-L1 therapy. In this review, we will focus on the regulation mechanism of PD-L1 expression, and describe the role of PD-1/PD-L1 binding on the anti-PD-1/PD-L1 therapy.

Ključne riječi

Immune checkpoint; PD-L1 expression; Signal pathway; Regulation mechanism

Hrčak ID:

186963

URI

https://hrcak.srce.hr/186963

Datum izdavanja:

29.9.2017.

Posjeta: 2.292 *